Pandemic experts are starting to sound increasingly optimistic. Is it safe to make plans for a summer vacation? - Yahoo News

Poison control is fielding calls from people using high doses of ivermectin obtained from veterinary offices in a flawed attempt to prevent COVID-19.

Moderna missed EPS expectations with revenue far surpassing analyst forecasts as the company first began to recognize revenue from sales of its COVID-19 vaccine in December 2020.

In 2021, Moderna plans to manufacture 600-700 million doses of its COVID-19 vaccine but it should be able to expand its capacity to 1.4 billion doses in 2022 due to heavy capital investments, all of which should result in massive profits.

Q4 and FY 2020 For the fourth quarter ended December 31, Moderna reported a quarterly loss of $0.69 per share, which was below Zacks Consensus Estimate of $0.25.

Just one year ago, revenues amounted to $14.06 million but until its mRNA-1273 coronavirus vaccine, the company had never brought an approved medicine to the market.

Although a big portion of revenue still came from the grant received from the Biomedical Advanced Research and Development Authority to advance its COVID vaccine, for the first time, Moderna had product sales, and they amounted to $199.87 million as the company began recognizing COVID vaccine sales in December.

Teenagers In early December, Moderna began a phase 2/3 trial of its COVID vaccine in young adults who are 12 to 17years old.

2021 The company expects $18.4 billion in full-year 2021 sales of its COVID vaccine.

Furthermore, the company said it plans to make 700 million doses of its vaccine this year, while still working to bring that capacity up to 1 billion.

In 2022, Moderna expects to be able to produce 1.4 billion doses.

Chief Executive Stephane Bancel called 2020 a historic year for the company as it trailed Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) by a week in the U.S by gaining emergency use authorization.

The vaccine is Moderna's first commercial product with 32 million doses having been administered in the U.S.

In 2020, Moderna went from knowing mRNA vaccines can be highly efficient it went to cash-flow generating commercial company that is helping save the world from the claws of an invisible enemy.

The latest reported quarter ended a milestone year for the biotech company.

2020 was a year in which the world went dark but the pandemic helped Moderna shine as it provided us with a glimpse of light at the end of the tunnel.